The virus might already be circulating in ways we can't see yet
Em junho de 2022, o Brasil registrou seu primeiro caso confirmado de varíola dos macacos em São Paulo, marcando a chegada de um vírus que, até então, circulava sobretudo em regiões endêmicas da África. Um homem de 41 anos, recém-chegado da Espanha, tornou-se o ponto de entrada de uma doença que já se espalhava por 31 países ao redor do mundo. O que inquietou as autoridades não foi apenas esse caso isolado, mas a possibilidade de que cadeias de transmissão local já estivessem se formando silenciosamente — antes mesmo de o país ter tempo de se preparar.
- Um homem de 41 anos hospitalizado em São Paulo após retornar da Espanha confirmou o que muitos temiam: o vírus havia cruzado o Atlântico e chegado ao Brasil.
- Uma mulher de 26 anos sem histórico de viagens internacionais e sem contato conhecido com infectados tornou-se suspeita, acendendo o alerta para uma possível transmissão comunitária já em curso.
- Sete casos suspeitos distribuídos por seis estados — do Sul ao Norte do país — revelaram que o vírus não estava contido em um único ponto, mas potencialmente em movimento por todo o território.
- Com 1.077 casos confirmados em 31 países e a maioria da população mundial sem vacinação contra varíola há mais de quarenta anos, o sistema de saúde global enfrenta uma janela de vulnerabilidade coletiva.
- Autoridades reforçam medidas preventivas básicas enquanto aguardam resultados de casos suspeitos, cientes de que a pergunta já não é se o vírus se estabelecerá em novos territórios, mas com que velocidade.
No início de junho de 2022, o Brasil confirmou seu primeiro caso de varíola dos macacos: um homem de 41 anos, morador de São Paulo, que havia retornado recentemente da Espanha. Internado no Hospital Emílio Ribas em isolamento, ele se tornou o marco de uma nova fase da doença no país. Ao mesmo tempo, as autoridades investigavam uma segunda suspeita — uma mulher de 26 anos sem viagens recentes e sem contato conhecido com infectados, detalhe que levantou a possibilidade de transmissão local já em andamento.
O cenário nacional era mais amplo do que um caso isolado sugeria. Sete suspeitas adicionais estavam sob investigação em seis estados: Santa Catarina, Rondônia, Ceará, Rio Grande do Sul e Mato Grosso do Sul. Um caso no Ceará já havia sido descartado, mas a dispersão geográfica indicava que o vírus circulava pelo país de forma difusa.
No plano global, a situação se acelerava: 31 países haviam confirmado 1.077 infecções, a maioria em nações africanas onde a doença é endêmica, mas com presença crescente em regiões onde nunca havia circulado antes. A varíola dos macacos se transmite por gotículas respiratórias em contato prolongado, por lesões, fluidos corporais e materiais contaminados. Os sintomas incluem febre, dor de cabeça intensa, gânglios inflamados e uma erupção cutânea que evolui ao longo de duas a quatro semanas.
A doença é significativamente menos letal do que a varíola humana — taxa de mortalidade entre 3% e 6%, contra 30% da varíola erradicada em 1980. A maioria dos pacientes se recupera com cuidados de suporte, embora grupos vulneráveis enfrentem riscos maiores. As vacinas contra varíola humana oferecem proteção cruzada, mas foram descontinuadas há décadas, deixando a maior parte da população mundial desprotegida. Nenhuma vacina específica contra varíola dos macacos estava disponível no mercado, embora autoridades reconhecessem que fabricantes poderiam ser mobilizados caso os casos continuassem a crescer.
Enquanto o Brasil aguardava os resultados dos casos suspeitos, a questão central havia mudado de tom: não se tratava mais de saber se o vírus se instalaria em novos territórios, mas de entender com que velocidade avançaria — e se os sistemas de saúde estariam prontos para recebê-lo.
Brazil recorded its first confirmed case of monkeypox in early June, a 41-year-old man living in São Paulo who had recently returned from Spain. He was admitted to Emílio Ribas Hospital and placed in isolation. The confirmation came as health authorities in the city were already investigating a second suspected case—a 26-year-old woman with no record of recent international travel and no known contact with infected people, a detail that raised the possibility of local transmission chains already forming.
The arrival of the virus in Brazil was not an isolated incident. Across the country, seven additional suspected cases were under investigation: two in Santa Catarina, two in Rondônia, one each in Ceará, Rio Grande do Sul, and Mato Grosso do Sul. One case in Ceará had already been ruled out. The geographic spread suggested the virus was moving through the country's population, though most cases remained unconfirmed.
Globally, the situation was accelerating. By that point in June, at least 31 countries had reported confirmed cases, totaling 1,077 infections. The majority of these occurred in African nations where monkeypox is endemic, but the virus was now establishing itself in regions where it had never circulated before, a shift that concerned public health officials worldwide.
Monkeypox spreads primarily through respiratory droplets, though the virus requires prolonged close contact to transmit this way. It can also spread through direct contact with lesions, bodily fluids, or contaminated materials, and through bites or consumption of infected animals. The incubation period ranges from five to twenty-one days. Once symptomatic, patients typically experience one to three days of fever, severe headache, swollen lymph nodes, back pain, and muscle aches. A rash then develops over two to four weeks, beginning as flat lesions and progressing to painful, raised bumps.
The disease is far less lethal than its human counterpart. The World Health Organization reported a mortality rate between three and six percent for monkeypox, compared to thirty percent for the smallpox virus that killed millions before its eradication in 1980. Most patients recover with supportive care—pain relievers and fever reducers—though severe cases can occur in pregnant women, elderly people, young children, and those with compromised immune systems.
Vaccines against human smallpox also protect against monkeypox, but mass vaccination campaigns were not yet being recommended. The smallpox vaccine had been discontinued worldwide after the disease's eradication four decades earlier, leaving most of the global population unvaccinated. Those who had received the vaccine more than forty years prior might retain some immunity. No monkeypox vaccines were currently available on the market, though health authorities acknowledged that if cases continued to rise, manufacturers could be mobilized to produce them.
Prevention relied on the familiar measures: avoiding contact with suspected cases and their belongings, wearing masks, maintaining distance, and steering clear of potentially infected animals. As Brazil waited for results on its suspected cases and the world watched the virus spread across new territories, the question was no longer whether monkeypox would establish itself in countries where it had never been seen before, but how quickly it would move and what that movement would mean for public health systems unprepared for it.
Notable Quotes
The smallpox vaccine protects against monkeypox, but mass vaccination is not yet recommended and no vaccines are currently available on the market— Brazilian health authorities
The Hearth Conversation Another angle on the story
Why does a single case in São Paulo matter enough to announce it nationally?
Because it's the first. Once a virus crosses into a new country, you're no longer dealing with imported cases—you're dealing with the possibility that it's already spreading locally. That 26-year-old woman with no travel history, that's the signal.
But the mortality rate is only three to six percent. Isn't that manageable?
Manageable compared to smallpox, yes. But it's still a virus that hospitalizes people, that causes weeks of painful lesions, that spreads through close contact. And we have no vaccine ready. The question isn't whether three percent is acceptable—it's whether we can contain it before those percentages start applying to thousands of people.
Why would they stop vaccinating against smallpox if the vaccine also protects against monkeypox?
Because smallpox was eradicated. Once a disease is gone, you stop vaccinating for it. That made sense in 1980. But it also means most people alive today have no immunity to monkeypox, even though the vaccine exists. If this spreads, we'd have to restart production from scratch.
The woman with no travel history—does that mean it's already spreading person to person in Brazil?
It suggests that possibility. One case from Spain is a traveler bringing a virus home. A second case in someone who didn't travel and didn't know an infected person? That's a different story. It means the virus might already be circulating in ways we can't see yet.
What happens next?
They wait for test results on those seven other suspected cases. They trace contacts. They watch to see if the woman's case leads to more cases, or if it was an isolated incident. And they hope the virus doesn't do what it's doing in thirty other countries—establish itself and keep spreading.